Moximed develops innovative therapies for patients with knee osteoarthritis.
Moximed has raised $61.0M in total funding. The most recent round was Series D. The last funding was announced in August 2024.
Moximed's investors include New Enterprise Associates, Vertex Ventures, Cormorant Asset Management, Frazier Healthcare Partners, Vertex Ventures HC.
Moximed is headquartered in Hayward, United States.
Moximed develops innovative therapies for patients with knee osteoarthritis.
Moximed is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Moximed — Funding & Investors." VCBacked, August 13, 2024, https://www.vcbacked.co/company/moximed. Accessed September 3, 2026.
VCBacked. (2024). Moximed — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/moximed
{{cite web |title=Moximed — Funding & Investors |url=https://www.vcbacked.co/company/moximed |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated